Company intelligence / Profile preview

Nereus Trust

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

Nereus Pharmaceuticals specialized in the discovery and clinical development of marine-derived small molecule drug candidates, particularly for oncology. As of its acquisition in 2012, its lead compounds (plinabulin/NPI-2358 and salinosporamide A/NPI-0052) had entered Phase I trials for various cancers, and multiple preclinical programs were reported for oncology, infectious disease, and inflammation.[1][2][4]

Therapeutic areas: OncologyImmunology
Modalities: Small molecule
Industry: Biotech

Partnerships

University of California, San Diego (licensing for microbial methods)

Beyond the preview

Go deeper on Nereus Trust.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nereus Trust.

Explore the full profile